Injectable pharmaceutical composition for the treatment of respiratory diseases in animals
An injectable composition using a compound of formula (I) in a medium chain triglyceride carrier effectively treats animal respiratory diseases with minimal injection site irritation, addressing the need for effective treatment without injury.
Patent Information
- Application Number
- JP2024537407
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-24
- Filing Date
- 2022-12-23
- Publication Date
- 2024-11-29
AI Technical Summary
There is a need for injectable pharmaceutical compositions that effectively treat respiratory diseases in animals without causing unacceptable injection site injuries.
Development of an injectable pharmaceutical composition comprising a compound of formula (I) or its pharmaceutically acceptable salt, suspended in a medium chain triglyceride carrier, with optional surfactants, to deliver the compound to the blood and lungs of animals, minimizing injection site irritation.
The composition effectively treats respiratory diseases in animals by delivering the compound to the bloodstream and lungs while maintaining minimal injection site irritation, resolving within a few days.
Smart Images

Figure 2024544415000001_ABST
Abstract
Description
[Background technology]
[0001] WO 2018 / 115432 discloses compounds for use in the treatment of animal respiratory diseases, in particular bovine or porcine respiratory diseases.
[0002] Bovine Respiratory Disease (BRD) is the most common and costly disease affecting beef cattle worldwide. Bovine Respiratory Disease (BRD) has a multifactorial etiology and develops as a result of complex interactions between environmental factors, host factors, and pathogens. Environmental factors (e.g., weaning, transportation, mixing, crowding, severe weather, dust, and inadequate ventilation) act as stressors that adversely affect the host's immune and non-immune defense mechanisms. In addition, certain environmental factors (e.g., crowding and inadequate ventilation) may facilitate the transmission of infectious agents between animals. It is a complex bacterial infection that causes enzootic pneumonia in calves and other bovine animals and is likely to be fatal. The infection is usually the sum of three codependent factors: stress, an underlying viral infection, and an emerging bacterial infection. Diagnosis of the disease is complex because of the multiple possible causes.
[0003] The term swine respiratory disease (SRD) was used to describe pneumonia of multiple etiologies that causes clinical disease and poor weight gain late in the finishing process (15–20 weeks of age).
[0004] Injection site lesions can occur following the administration of animal health products. Injection site lesions are often scar tissue that forms in muscle or subcutaneous tissue after an injection. Packers trim the injection site lesions from the carcass and often trim the muscle tissue. Injection site lesions cause meat quality problems and must be prevented. See Imer, et al., "Cull Cow Beef Quality Issues: Injection Sties and Abscesses," AN308, Department of Animal Sciences, UF / IFAS Extension, https: / / edis.ifas.ufl.edu, first published October 2014 and reviewed October 2017.
[0005] There is a need for an injectable pharmaceutical composition that is an effective treatment for respiratory disease in animals and that is administered without causing unacceptable injection site injury. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2018 / 115432 [Non-patent literature]
[0007] [Non-Patent Document 1] Imer, et al., “Cull Cow Beef Quality Issues: Injection Sties and Abscesses” AN308, Department of Animal Sciences, UF / IFAS Extension Summary of the Invention
[0008] The present invention provides an effective amount of a compound of formula (I) [ka] or a pharma- ceutically acceptable salt thereof; A pharma- ceutically acceptable carrier; The present invention relates to an injectable pharmaceutical composition comprising: [Brief description of the drawings]
[0009] [Figure 1] Injection site reaction volume data for Compounds A and B are shown. [Diagram 2] Injection site reaction volume data for Compounds A and C are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] Injectable pharmaceutical compositions have been developed that are effective treatments for respiratory diseases such as Bovine Respiratory Disease (BRD) and Swine Respiratory Disease (SRD) and that do not result in unacceptable injection site injury when administered.
[0011] It has been determined that the compound of formula (I) is effective against bacteria known to cause respiratory disease in animals. Furthermore, the compound of formula (I) can be delivered to the blood and lungs of animals at acceptable concentrations when administered in the injectable pharmaceutical composition of the claimed invention. Furthermore, when the compound of formula (I) is administered to animals in the injectable pharmaceutical composition, injection site irritation is minimal, and the resulting irritation recovers or decreases to acceptable levels within a few days after administration.
[0012] Compound (A) is an enantiomer of the compound of formula (I). [ka]
[0013] Compound (A) was found to be active against microorganisms that cause respiratory disease in animals and to be bioavailable in effective amounts in the blood and lungs of animals. When administered to animals by injection, compound (A) was tolerated at the injection site. This is not true for other compounds with similar structures to compound (A). Compounds (B) and (C) were also active against microorganisms that cause respiratory disease in animals, but it has been determined that injectable pharmaceutical compositions containing compounds (B) and (C) cause unacceptable injection site reactions when administered to cattle. (See Example 4 below)
[0014] [Table 1]
[0015] These results were unexpected.
[0016] Pharmaceutically acceptable salt refers to an acid or base salt of the compound of the present invention that is of sufficient purity and quality to be used in the formulation of the composition or medicament of the present invention, and is sufficiently non-toxic to be acceptable for use in pharmaceutical preparations. Suitable pharmaceutically acceptable salts include acid addition salts, which can be formed, for example, by reacting a drug compound with a suitable acid, such as hydrobromic acid, hydrochloric acid, sulfuric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
[0017] A pharma- ceutically acceptable carrier is a material that is capable of transporting the active ingredient(s) to the required location on or in the patient and that is compatible with the other ingredients of the formulation.
[0018] The pharma- ceutically acceptable carrier may form a solution or suspension with the active ingredient(s). A salt of the active ingredient is often suspended in an oily carrier. The free base form of the active ingredient is often dissolved in an aqueous carrier.
[0019] In the injectable pharmaceutical composition that is a suspension, the pharma- ceutically acceptable carrier can be an oil. In some embodiments, the oil can be a fatty acid ester. A fatty acid ester (FAE) is a type of ester resulting from the combination of a fatty acid with an alcohol. When the alcohol component is glycerol, the fatty acid ester produced can be a monoglyceride, a diglyceride, or a triglyceride. Preferably, the fatty acid ester is a medium chain triglyceride (MCT).
[0020] Medium chain triglycerides are oil-based pharma- ceutical acceptable carriers and can be any triglyceride having 2-3 fatty acids with an aliphatic tail of 6-12 carbon atoms. More specifically, MCTs are triglycerides having C8-C 10 It contains either triglycerides of fatty acids or propylene glycol diesters of these fatty acids, or a mixture of both triglycerides and propylene glycol diesters. Preferably, MCTs contain saturated fatty acids, primarily caprylic acid (C8H 16 O2) and capric acid (C 10 H 20 O2). USP-NF, Interim Revision Announcement Official (March 1, 2019). They are conveniently prepared by commercial fractionation of natural vegetable (e.g. coconut) oils to obtain primarily C8-10 fatty acids, followed by esterification of these acids with selected alcohols. Fractionated vegetable oils with the desired composition are commercially available. Trademarked examples of such MCT oils are Miglyol® 812 as capric / caprylic triglyceride and Miglyol® 840 as propylene glycol dicaprylate / caprate.
[0021] The concentration of the active ingredient in the injectable composition is about 1 to about 70% (w / v). In some such embodiments, it is about 1 to about 50% (w / v) or about 10 to about 50% (w / v). In other embodiments, the concentration is about 35 to about 65% (w / v), about 40 to about 60% (w / v), about 45 to about 55% (w / v), or about 50% (w / v).
[0022] In the injectable pharmaceutical compositions of the present invention, the amount of the compound of formula (I) is about 10% w / v to about 35% w / v, about 15% w / v to about 30% w / v, about 10% w / v to about 25% w / v, about 20% w / v to about 30% w / v, or about 25% w / v of the composition.
[0023] The injectable pharmaceutical composition of the present invention can deliver a milligram dose of the active ingredient (compound of formula (I)) per kg of animal body weight of about 5 mg / kg to about 25 mg / kg, or about 10 mg / kg to about 20 mg / kg, or about 10 mg / kg, or about 15 mg / kg, or about 20 mg / kg.
[0024] The injectable pharmaceutical composition according to the present invention may also contain a surfactant.
[0025] A surfactant is a substance that, when added to a liquid, reduces its surface tension, thereby increasing its spreading and wetting properties. A surfactant must be partially hydrophilic (water-soluble) and partially lipophilic (soluble in lipids or oils). Examples are polyethylene glycol (15)-hydroxystearate, poloxamer, D-α-tocopheryl polyethylene glycol 1000 succinate, polysorbate 80 and lecithin. A preferred example is polyethylene glycol (15)-hydroxystearate.
[0026] Poloxamers are block copolymers composed of a central block of hydrophobic polyoxypropylene (poly(propylene oxide)) bound at each end by two blocks of hydrophilic polyoxyethylene (poly(ethylene oxide)) (see U.S. Pat. No. 3,740,421 and P. Alexandridis, TA Hutton, Colloids Surfaces A: Physiochem. Eng. Aspects 96 (1995) pp 1-46). Examples are poloxamer 188, poloxamer 407 and poloxamer 124.
[0027] In the injectable pharmaceutical composition according to the invention which is an aqueous solution, the carrier may be water. Along with water, co-solvents may also be incorporated into the injectable pharmaceutical composition.
[0028] A co-solvent is a solvent that can be combined with another solvent to dissolve a solute. Potential co-solvents for aqueous solutions can include propylene glycol, polyethylene glycol (PEG) 200, 300 and 400, 2-pyrrolidone, N-methylpyrrolidone, N,N-dimethylacetamide, glycofural, glycerol formal, glycerin, ethanol, dimethyl sulfoxide, and diethylene monoethyl ether or mixtures thereof.
[0029] Injectable pharmaceutical compositions can be administered via intramuscular or subcutaneous routes.
[0030] The injectable pharmaceutical compositions can be administered to treat bacterial infections in animals.The compositions can be administered to treat respiratory diseases in animals.
[0031] Bacterial agents frequently associated with many of the respiratory diseases in cattle, including BRD, are Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. Actinobacillus pleuropneumoniae is a gram-negative bacterium and the most common cause of pleuropneumonia in pigs. P. multocida is a gram-negative bacterium that is the cause of atrophic rhinitis and pneumonia in pigs and pneumonia in ruminants. Bordetella bronchiseptica is a Gram-negative bacterium that induces infection with virulent strains of P. multocida, which cause rhinitis and mild to moderate turbinate atrophy, progressing from atrophic rhinitis. Glaesserella parasuis is a Gram-negative bacterium that causes Glasser's disease, a common pathology seen in young pigs, characterized by polyarthritis, polyserositis and meningitis.
[0032] The animal may be a domestic animal, in particular a cow or a pig.
[0033] Exemplary animals include, but are not limited to, medium to large ungulates, such as domestic dairy and beef cattle, members of the biological subfamily Bovinae, such as bison, African buffalo, water buffalo, etc. The animals may be so-called livestock raised in an agricultural environment for the production of dairy products or meat, or may be raised for work, or may be in another environment, such as a zoo, animal sanctuary, etc., or may be raised for some other reason, such as as pets, entertainment animals, for breeding purposes, etc.
[0034] The use of the injectable pharmaceutical composition of the present invention in beef cattle is particularly preferred. Beef cattle are cattle raised for meat production (as distinguished from dairy cattle used for milk production). There are three main stages in beef production: cow-calf operation, backgrounding, and feedlot operation. The use of the injectable pharmaceutical composition of the present invention in beef cattle in feedlot (feedyard) operation is particularly preferred. The injectable pharmaceutical composition of the present invention can be used in beef cattle (and dairy cattle), calves, heifers, steers, or cows of any age. The injectable pharmaceutical composition of the present invention can be used in animals of different weights, including calves weighing 80 kg to 150 kg, as well as large animals weighing more than 350 kg.
[0035] Other exemplary animals that may be treated with the compositions of the present invention are small ruminants, such as sheep or goats, or pseudoruminants, such as camels or llamas.
[0036] The injectable pharmaceutical composition of the present invention can alternatively be used to treat porcine respiratory disease (SRD), a disease of animals of the porcine family, commonly referred to as pigs or swines. The composition of the present invention can generally be administered to all porcine animals, pre-weaned, post-weaned, boars, castrators, gilts or sows. The injectable pharmaceutical composition can be used in one or more of the stages of swine production for meat: suckling pigs, feeding pigs, growing and finishing pigs, or fattening pigs back. Alternatively, the injectable pharmaceutical composition can be used in breeding livestock, i.e. breeding sows, gilts or boars, or the progeny of such animals as replacement breeding livestock.
[0037] In one embodiment, the animal being treated is a bovine animal and the disease being treated is BRD.
[0038] In another embodiment, the animal being treated is a boar (pig) animal and the disease being treated is SRD.
[0039] The injectable pharmaceutical composition of the present invention can be used to treat diseased animals exhibiting clinical symptoms of bovine respiratory disease or porcine respiratory disease.
[0040] In one embodiment, the injectable pharmaceutical composition of the present invention is used to treat respiratory diseases in lambs and / or adult sheep (ewes, rams) kept for meat or as breeding livestock, such as enzootic pneumonia, an acute infectious disease of sheep characterized by fever, nasal discharge, interstitial pneumonia and pleurisy.
[0041] Additionally or alternatively, the injectable pharmaceutical composition of the present invention can be used to treat animals with subclinical infections due to infection with Pasteurella spp., Mannheimia spp. and Histophilus spp. Subclinical infections are almost or completely asymptomatic (without signs or symptoms of disease) and are mainly detected during lung examination for lesions at slaughterhouses. However, subclinical BRD or SRD infections are commercially very relevant as they reduce the average daily weight gain of infected animals, which are also a source of infection for contact animals.
[0042] In addition to therapeutic purposes, the injectable pharmaceutical composition of the present invention is also suitable for prophylactic use. For example, in the case of an outbreak of bovine respiratory disease or porcine respiratory disease, the injectable pharmaceutical composition of the present invention can be administered to non-diseased (or subclinically infected) animals, especially to animals in close contact with animals showing clinical signs of disease, to prevent the spread of infection. The injectable pharmaceutical composition of the present invention is also useful for the prophylactic treatment of bovine respiratory disease in animals in feedlots.
[0043] Additionally, prophylactic treatment can be performed in cattle that are considered vulnerable to infection and / or where infection may have serious consequences, whether or not disease outbreaks are known to have occurred, such as calves, show cows, pregnant cows, prize-winning bulls or bulls, etc. Another option is to prophylactically administer an injectable pharmaceutical composition according to the present invention to animals prior to shipping and other stress-inducing events to prevent disease outbreaks in such animals.
[0044] The same preventative or prophylactic treatment concepts described in the preceding paragraph apply to porcine animals at risk of SRD.
[0045] The concentration of the compound of formula (I) in the injectable pharmaceutical composition according to the invention is sufficient to provide the desired therapeutically effective amount in a volume acceptable for parenteral (subcutaneous) administration, allowing injection volumes of less than 20 ml, preferably less than 10 ml per injection site.
[0046] The injectable pharmaceutical compositions according to the invention are packaged in suitable containers containing single or multiple doses ready for administration (ready to use - RTU).
[0047] Further embodiments Embodiment 1. An effective amount of a compound of formula (I) [ka] or a pharma- ceutically acceptable salt thereof; A pharma- ceutically acceptable carrier; 13. An injectable pharmaceutical composition comprising:
[0048] Embodiment 2. The compound of formula (I) is a compound of formula (A): [ka] 2. An injectable pharmaceutical composition according to embodiment 1.
[0049] Embodiment 3. The injectable pharmaceutical composition of embodiment 1 or 2, wherein the compound is the dihydrochloride salt of the compound of formula (I).
[0050] Embodiment 4. An injectable pharmaceutical composition according to any one of embodiments 1 to 3, wherein the amount of the compound of formula (I) is from about 10% w / v to about 35% w / v, from about 15% w / v to about 30% w / v, from about 10% w / v to about 25% w / v, from about 20% w / v to about 30% w / v, or about 25% w / v of the composition.
[0051] Embodiment 5. An injectable pharmaceutical composition according to any one of embodiments 1 to 4, wherein the pharma- ceutically acceptable carrier is a medium chain triglyceride and the compound of formula (I) forms a suspension in the medium chain triglyceride.
[0052] Embodiment 6. The injectable pharmaceutical composition of embodiment 5, wherein the composition further comprises a surfactant.
[0053] Embodiment 7. The injectable pharmaceutical composition of embodiment 6, wherein the amount of surfactant is about 0.01% w / v to about 1.0% w / v.
[0054] Embodiment 8. An injectable pharmaceutical composition according to any one of embodiments 6 to 7, wherein the surfactant is polyethylene glycol (15)-hydroxystearate, poloxamer, D-α-tocopheryl polyethylene glycol 1000 succinate, polysorbate 80 or lecithin.
[0055] Embodiment 9. The injectable pharmaceutical composition of embodiment 8, wherein the surfactant is polyethylene glycol (15)-hydroxystearate.
[0056] Embodiment 10. An injectable pharmaceutical composition according to any one of embodiments 1 to 4, wherein the pharma- ceutically acceptable carrier is water and the compound of formula (I) forms a solution in the water.
[0057] Embodiment 11. The injectable pharmaceutical composition of embodiment 10, wherein the composition further comprises a surfactant.
[0058] Embodiment 12. The injectable pharmaceutical composition of embodiment 11, wherein the surfactant is selected from benzyl alcohol, poloxamer 124, citric acid, or a mixture thereof.
[0059] Embodiment 13. a) About 10% to about 35% w / v of the dihydrochloride salt of the compound of formula (A). [ka] b) about 0.01 to about 1% w / v polyethylene glycol (15)-hydroxystearate, and c) Medium Chain Triglycerides (QS) 13. An injectable pharmaceutical composition comprising:
[0060] Embodiment 14. a) About 10% to about 35% w / v of a compound of formula (A) [ka] b) about 10% to about 20% w / v poloxamer; c) about 4% to about 8% w / v benzyl alcohol; d) about 5% to about 10% w / v citric acid, and e) Water (QS) 13. An injectable pharmaceutical composition comprising:
[0061] Embodiment 15. A method for treating a bacterial infection in an animal, comprising administering to the animal an effective amount of an injectable pharmaceutical composition according to any one of embodiments 1 to 14.
[0062] Embodiment 16. The method of claim 15, wherein the bacterial infection is caused by infection with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, or Glaesserella parasuis.
[0063] Embodiment 17. The method of any one of embodiments 15-16, wherein the animal is a bovine or porcine.
[0064] Embodiment 18. A method for treating a respiratory infection in an animal, comprising administering to the animal an effective amount of an injectable pharmaceutical composition according to any one of embodiments 1 to 14.
[0065] Embodiment 19 The method of embodiment 18, wherein the respiratory infection is bovine respiratory disease and the animal is a bovine animal.
[0066] Embodiment 20 The method of embodiment 18, wherein the respiratory infection is porcine respiratory disease and the animal is a pig.
[0067] Embodiment 21. An injectable pharmaceutical composition according to any one of embodiments 1 to 14 for use in treating a bacterial infection in an animal.
[0068] Embodiment 22. An injectable pharmaceutical composition for use according to embodiment 21, wherein the bacterial infection is caused by infection with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, or Glaesserella parasuis.
[0069] Embodiment 23. An injectable pharmaceutical composition for use according to any of embodiments 21 or 22, wherein the animal is a bovine or porcine.
[0070] Embodiment 24. An injectable pharmaceutical composition according to any one of embodiments 1 to 14 for use in treating a respiratory infection in an animal.
[0071] Embodiment 25. The injectable pharmaceutical composition for use according to embodiment 24, wherein the respiratory infection is bovine respiratory disease and the animal is a bovine animal.
[0072] Embodiment 26 The injectable pharmaceutical composition for use according to embodiment 24, wherein the respiratory infection is porcine respiratory disease and the animal is a pig.
[0073] Embodiment 27. An injectable pharmaceutical composition for use according to any one of embodiments 21 to 26, comprising administering to an animal an effective amount of the injectable pharmaceutical composition.
[0074] The invention will now be further illustrated by the following non-limiting examples.
[0075] [Example] [Example 1] An injectable pharmaceutical composition which is a suspension of the dihydrochloride salt of the compound of formula (A) [ka] [Table 2]
[0076] The following procedure was used to prepare 100 mL of the above suspension injectable pharmaceutical composition. 1. In a 150-250 mL PTFE beaker, 0.1 g of polyethylene glycol (15)-hydroxystearate (Kolliphor HS15) was mixed with 49.9 g of medium chain triglycerides. The mixture was then warmed in a water bath to a temperature of approximately 50 °C. Once the polyethylene glycol (15)-hydroxystearate was dissolved, the mixture was stirred until a homogenous clear solution was observed. 2.25 g of the dihydrochloride salt of the compound of formula (A) and about 10 g of medium chain triglyceride were added to the solution of step 1. The resulting mixture was homogenized using an IKA homogenizer (Model T25 Digital Ultra Turrax) equipped with an 18G shaft until a uniform suspension was observed. 3. The suspension from step 2 was transferred to a 100 mL volumetric flask. 4.5 mL of medium chain triglyceride was used to rinse the beaker and transferred to the volumetric flask. This rinsing procedure was repeated two times. An additional amount of medium chain triglyceride was added to bring the volume in the flask to 100 mL. The suspension was then mixed well by hand. 5. The suspension was transferred to a clean PTFE beaker and homogenized until the suspension was uniform.
[0077] [Example 2] An injectable pharmaceutical composition which is a solution of a compound of formula (A) [ka] [Table 3]
[0078] The following procedure was used to prepare 100 mL of the above aqueous injectable pharmaceutical composition. 1. Citric acid anhydride, poloxamer P124, benzyl alcohol and 55g water for injection (or 55% of the target volume of the final product) were added to a volumetric flask. The mixture was stirred using a magnetic stirrer until the solution was clear. 2. Compound A was added to the flask and mixed overnight using a magnetic stirrer. The composition was opaque or cloudy. A 30% citric acid solution was added dropwise with mixing until the pH was in the range of 4-4.5. 3. The solution from step 2 was mixed until clear. 4. The solution was mixed overnight. The pH was checked and adjusted to pH 4-4.5 by adding additional amounts of 30% citric acid solution and 1N sodium hydroxide solution. 5. QS with Water for Injection. Mix well.
[0079] [Example 3] Antibacterial activity of the compounds of formula (I) In this study, the in vitro activity of compound (A), the enantiomer of compound of formula (I), against different isolates of Actinobacillus (A.) pleuropneumoniae, Bordetella (B.) bronchiseptica, Mannheimia (M.) haemolytica, Pasteurella (P.) multocida, Histophilus (H.) somni and Glaesserella parasuis collected in different European countries was determined.
[0080] In vitro activity was determined by measuring the minimum inhibitory concentration (MIC) according to CLSI document VET01-A4[1]. MIC 50 and MIC 90 was determined by calculating
[0081] A total of 193 field isolates were tested: 31 A. pleuropneumoniae, 20 B. bronchiseptica, 20 H. somni, 20 H. parasuis, 55 M. haemolytica and 47 P. multocida. All bacteria were isolated from the respiratory tract of cattle and pigs suffering from respiratory disease. All isolates were epidemiologically unrelated when identified by different suppliers.
[0082] E. coli ATCC 25922 (ID 6105) and M. haemolytica ATCC 33396 (ID 6374) were used as reference strains for testing isolates of B. bronchiseptica, M. haemolytica, and P. multocida. A. pleuropneumoniae ATCC 27090 (ID 6314) and H. somni ATCC 700025 (ID 6315) were used as reference strains for testing isolates of A. pleuropneumoniae, H. somni, and Glaesserella parasuis. Additionally, G. parasuis ATCC 19417 was included as a representative strain for growth control. The MICs obtained for compound A against the reference strains are shown in Table 1.
[0083] Culture media and supplements Mueller-Hinton Agar (Becton Dickinson, lot 9224866) Cation-adjusted Mueller-Hinton Broth, (CAMHB, Becton Dickinson, lot 8190586) Sheep blood, defibrillated (Thermo Scientific, lot 37091500) Chocolate agar, GC II with IsoVitalex™ (Becton Dickinson, lot 0147695) GC-Agar Base (Becton Dickinson, Lot 6082608) Hemoglobin solution (Becton Dickinson, lot 7142854) Vitox (Oxoid, lot 2344976) Veterinary fastidious medium (VFM), prepared according to CLSI document VET01-A4[1]; Includes: o CAMHB (Becton Dickinson, lot 8190586) o Yeast extract (Sigma, lot BCBS5470V) Lysed horse blood (Thermo Scientific, lot 35875000) Supplement C™ (Becton Dickinson, Lot 8030960) Deionized water
[0084] The medium was prepared according to the manufacturer's instructions.
[0085] MICs for all isolates, except H. somni and Glaesserella parasuis isolates, were determined using the broth microdilution method according to CLSI document VET01-A4 [1]. For H. somni and Glaesserella parasuis isolates, the agar dilution method with chocolate agar GC II was used. The test concentration range for all compounds was 16 μg / mL to 0.016 μg / mL.
[0086] MIC results were interpreted according to CLSI document VET01-S3[2]. The MIC is the lowest concentration of antimicrobial agent that completely inhibits the growth of an organism. All wells containing test items were compared to growth control wells. The lowest concentration of compound at which no visible growth was detected by the naked eye (i.e., no turbidity) was recorded as the MIC. If a "trailing endpoint" occurs, the MIC is defined as the first concentration at which a significant reduction (approximately 90%) of the inoculum is observed.
[0087] For isolates tested by agar dilution, results were interpreted according to CLSI document VET01-S3[2]. The MIC is the lowest concentration of an antimicrobial agent that completely inhibits colony formation, ignoring the slight turbidity caused by a single colony or inoculum. MIC 50 and MIC 90 represents the concentration at which at least 50% or 90% of the isolates tested are inhibited.
[0088] [Table 4]
[0089] 1. Clinical Laboratory Standards Institute (CLSI) Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard-fourth edition. CLSI document VET01-A4. (ISBN 1-56238-878-9). CLSI, Wayne, Pennsylvania 19087, USA, 2013. 2. Clinical Laboratory Standards Institute (CLSI)Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; third informational supplement. CLSI document VET01S 3 rd edition.(electronic ISBN 1-56238-908-4).CLSI, Wayne, Pennsylvania 19087, USA, 2015.
[0090] [Example 4] Injection site reactions Cattle injected with an injectable pharmaceutical composition containing compound (A) were evaluated for reactions at the injection site, and these injection site reactions were compared to those of cattle injected with injectable pharmaceutical compositions containing compounds (B) and (C).
[0091] [Table 5]
[0092] The compounds were formulated as aqueous injectable pharmaceutical compositions or as suspension injectable pharmaceutical compositions as shown below: These formulations were prepared as described in Examples 1 and 2.
[0093] Compound (A) was formulated as both an aqueous solution using the free base form of the compound, and a suspension using the dihydrochloride salt of the compound. The composition of the aqueous solution injectable pharmaceutical composition was 15% w / v compound A, 15% w / v poloxamer P124, 6% w / v benzyl alcohol, 7% w / v citric acid, and QS water. The composition of the suspension injectable pharmaceutical composition was 15% w / v compound A (17.5% w / v HCl salt of compound A), 0.1% w / v Kolliphor HS 15, and QS Miglyol 812. Compound A was administered to animals at a dose of 10 mg / kg body weight.
[0094] Compound (B) was formulated as both an aqueous solution using the free base form of the compound, and a suspension using the dihydrochloride salt of the compound. The composition of the aqueous solution injection pharmaceutical composition was 15% w / v compound B, 15% w / v poloxamer P124, 6% w / v benzyl alcohol, 7% w / v citric acid, and QS water. The composition of the suspension injection pharmaceutical composition was 15% w / v compound B (17.5% w / v HCl salt of compound B), 0.1% w / v Kolliphor HS 15, and QS Miglyol 812. Compound A was administered to animals at a dose of 10 mg / kg body weight.
[0095] Compound (C) was formulated as both aqueous solutions using the free base form of the compound. The composition of the aqueous injection pharmaceutical composition was 10% w / v compound C, 15% w / v poloxamer P124, 6% w / v benzyl alcohol, 7% w / v citric acid, and QS water. Compound A was administered to animals at a dose of 10 mg / kg body weight.
[0096] Injection sites were clinically examined by trained personnel.
[0097] The size of the swelling was measured using a ruler with precision to the nearest 0.5 cm in width, length and depth. These three measurements were multiplied to estimate the volume of a square box surrounding the observed swelling.
[0098] Injection site reaction data is shown in Table 2 below. [Table 6]
[0099] FIG. 1 shows the injection site reaction volume data for Compounds A and B.
[0100] FIG. 2 shows the injection site reaction volume data for Compounds A and C.
[0101] As these data show, Compound A produced minor injection reactions that resolved by day 6. Compounds B and C produced more severe injection reactions than Compound A, and these injection site reactions did not resolve over the course of the study.
[0102] [Example 5] Pharmacokinetic analysis of compound A This study determined the bioavailability and pharmacokinetic profile of Compound A formulation for subcutaneous (SC) injection in bovine plasma following a single SC dose of 10 mg / kg body weight. Concentrations in plasma and bronchial epithelial lining fluid were determined. Additional tissues were collected postmortem for compound concentration determination.
[0103] Compound A was formulated as described above in Examples 1 and 2. The aqueous formulation was 15% w / v Compound A, 15 w / v Kollisolv P124, 6% w / v benzyl alcohol, 7% w / v citric acid and QS water, pH 5.2. The oil suspension formulation was 17.5% w / v Compound A suspended in 0.1% Kolliphor HS, and QS Miglyol 812.
[0104] Individual blood samples of approximately 4 mL per sample were taken from all animals on D-1 and at 15 min, 30 min, 1 h, 2 h, 4 h, 7 h, 10 h, 24 h, 32 h, 48 h, 72 h and 142 h (D6) after dosing. Samples were collected in K-EDTA coated Monovettes®. Samples were taken from the external jugular vein. The left side of the body opposite to dosing was preferred.
[0105] The tubes were gently shaken to ensure proper mixing of the blood and anticoagulant and placed in ice water until centrifugation. The K-EDTA-blood samples were centrifuged at approximately 4°C and a relative centrifugal force of 2000 for 10 min. Within 2 h of collection, two aliquots (1, 2) of approximately 0.5 mL of plasma were pipetted from each sample into labeled plastic (polypropylene) freezer vials.
[0106] Pharmacokinetic (PK) parameters (Table 10-2) were calculated using Phoenix WinNonlin 8.1 software. PK parameters (at least Cmax, Tmax, AUClast, HL_Lambda_Z, VZ_F, MRTlast, CL_F and F%) to describe the PK profile following SC compound administration.
[0107] [Table 7]
[0108] [Table 8]
[0109] [Table 9]
[0110] In both the aqueous and oil suspension groups, Compound A was detectable in bovine plasma for an average of 72 hours, with overall comparable PK plasma profiles. Both groups demonstrated high initial plasma levels, a significant steady plasma plateau level from 4-10 hours post-treatment, high systemic exposure in bovines, and a relatively short compound persistence of approximately 11 hours in bovines.
[0111] [Example 6] lung tissue research The same animals and compound A compositions used in Example 5 were also used for lung tissue studies. Trachea and accessory tissues were removed from the lungs. 1 / 2 of the lung was homogenized using a food processor (Robot Coupe). Two aliquots of approximately 1 g were placed in 15 mL Falcon tubes. Scissor pieces of liver, kidney and skeletal muscle (long dorsal muscle) from at least two locations were collected to a total mass of approximately 1 g each and placed in 15 mL Falcon tubes. Tissue samples were diluted with blank EDTA bovine plasma 1+3 (w / v) and samples were homogenized using the FastPrep™ system. After centrifugation, an aliquot of the supernatant was used to determine compound concentration by HPLC-MS / MS technique.
[0112] [Table 10]
[0113] Compound A is Significant amounts were detected in tissue samples from the lungs after sacrifice. Detected.
[0114] [Example 7] Efficacy studies The efficacy of Compound (A) as a one-shot treatment at 20 mg / kg is demonstrated in naturally occurring BRD outbreaks compared to an untreated control group (saline) and standard of care treatment (Draxxin™).
[0115] Animals are observed for 14 days after treatment. Respiratory and depression scores as well as morbidity and mortality are recorded.
Claims
1. An effective amount of a compound of formula (I) 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof; A pharma- ceutically acceptable carrier; 13. An injectable pharmaceutical composition comprising:
2. The compound of formula (I) is a compound of formula (A), 【Chemistry 2】 The injectable pharmaceutical composition according to claim 1.
3. 3. The injectable pharmaceutical composition according to claim 1 or 2, wherein the compound is the dihydrochloride salt of the compound of formula (I).
4. 4. The injectable pharmaceutical composition of any one of claims 1 to 3, wherein the amount of the compound of formula (I) is about 10% w / v to about 35% w / v, about 15% w / v to about 30% w / v, about 10% w / v to about 25% w / v, about 20% w / v to about 30% w / v, or about 25% w / v of the composition.
5. 5. The injectable pharmaceutical composition of any one of claims 1 to 4, wherein the pharma- ceutically acceptable carrier is a medium chain triglyceride and the compound of formula (I) forms a suspension in the medium chain triglyceride.
6. The injectable pharmaceutical composition of claim 5 , wherein the composition further comprises a surfactant.
7. 7. The injectable pharmaceutical composition of claim 6, wherein the amount of said surfactant is from about 0.01% w / v to about 1.0% w / v.
8. The injectable pharmaceutical composition according to any one of claims 6 to 7, wherein the surfactant is polyethylene glycol (15)-hydroxystearate, poloxamer, D-α-tocopheryl polyethylene glycol 1000 succinate, polysorbate 80 or lecithin.
9. The injectable pharmaceutical composition according to claim 8, wherein the surfactant is polyethylene glycol (15)-hydroxystearate.
10. The injectable pharmaceutical composition according to any one of claims 1 to 4, wherein the pharma- ceutically acceptable carrier is water and the compound of formula (I) forms a solution in water.
11. The injectable pharmaceutical composition of claim 10 , wherein the composition further comprises a surfactant.
12. 12. The injectable pharmaceutical composition of claim 11, wherein the surfactant is selected from benzyl alcohol, poloxamer 124, citric acid or a mixture thereof.
13. a) about 10% to about 35% w / v of the dihydrochloride salt of the compound of formula (A) 【Chemistry 3】 b) about 0.01 to about 1% w / v polyethylene glycol (15)-hydroxystearate, and c) Medium Chain Triglycerides (QS) 13. An injectable pharmaceutical composition comprising:
14. a) about 10% to about 35% w / v of a compound of formula (A) 【Chemistry 4】 b) about 10% to about 20% w / v of a poloxamer; c) about 4% to about 8% w / v benzyl alcohol; d) about 5% to about 10% w / v citric acid, and e) Water (QS) 13. An injectable pharmaceutical composition comprising:
15. An injectable pharmaceutical composition according to any one of claims 1 to 14 for use in the treatment of bacterial infections in animals.
Citation Information
Patent Citations
Injection for animal
JP1995082141A
Compounds for treating respiratory diseases in cattle or pigs
JP2020502214A
Sustained-release suspension containing dezocine analogue ester and method for producing same
JP2020527543A
Injectable isoxazoline pharmaceutical compositions and their use against parasitic infestations
JP2021501758A
Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof
WO2016039433A1
